Daniel Sikkema PhD

Dr. Sikkema is currently Vice President, Biopharmaceutical and Bioanalytical Services for Quanterix Corporation, and brings more than 25 years of experience in the biopharmaceutical, vaccine, and cell-gene therapy fields. He has held positions of increasing responsibility at Bristol-Myers Squibb, Wyeth Vaccines, Merck Vaccines, Sanofi Pasteur, Frontage Laboratories, and GlaxoSmithKline. In his career, he has contributed to the licensure of Prev(e)nar, Meningitec, Gardasil, RotaTeq, ProQuad, Zostavax, and Dengue vaccines, also Ofatumumab, Raxibacumab, Benlysta, Albiglutide, Mepolizumab, Denosumab, and other biopharmaceuticals, as well as Strimvelis the world’s first ex vivo cell/gene therapy product. He has also worked with the WHO, NIBSC, US CDC, FDA, and EMA in roles as an invited expert and as an advisor including Gene Therapy approaches for Hemophilia for FDA.

Dr. Sikkema earned a Ph.D. in Microbiology and Public Health from Michigan State University, College of Medicine. He was a Post-Doctoral Fellow in Infectious Diseases at SUNY at Buffalo, School of Medicine. He has Chaired Division V for the American Society for Microbiology and was Coordinator for an Innovative Medicine Initiative project ABIRISK, the largest funded project to study Immunogenicity of Biotherapeutics. He has authored 30 peer-reviewed publications and has delivered more than 80 public presentations globally at scientific symposia.